AI Engines For more Details: Perplexity Kagi Labs You
Cognitive Function: Citicoline has been studied for its potential role in supporting cognitive function and brain health. Some research suggests that citicoline supplementation may improve memory, attention, and other cognitive functions, particularly in older adults and individuals with cognitive impairment or neurodegenerative disorders like Alzheimer's disease and dementia.
Stroke Recovery: Citicoline has been investigated for its potential neuroprotective effects and its ability to enhance recovery following ischemic stroke, a type of stroke caused by a blockage in a blood vessel supplying the brain. Studies have shown that citicoline supplementation may improve neurological outcomes and functional recovery in stroke patients when used as part of their treatment regimen.
Traumatic Brain Injury (TBI): Citicoline has also been studied for its potential benefits in individuals with traumatic brain injury (TBI). Research suggests that citicoline supplementation may help reduce neurological deficits and improve cognitive function in patients recovering from TBI by supporting the repair and regeneration of damaged brain tissue.
Glaucoma: Some studies have investigated the use of citicoline eye drops for the treatment of glaucoma, a condition characterized by increased pressure within the eye that can lead to vision loss. Citicoline eye drops have been shown to have neuroprotective effects on retinal ganglion cells, which are damaged in glaucoma, and may help preserve vision and slow the progression of the disease.
Addiction Treatment: Citicoline has been explored as a potential adjunctive treatment for substance use disorders, including addiction to drugs such as cocaine, methamphetamine, and nicotine. Preliminary research suggests that citicoline supplementation may help reduce cravings, improve mood, and support recovery from addiction by modulating neurotransmitter systems involved in reward processing and addiction-related behaviors.
Attention-Deficit/Hyperactivity Disorder (ADHD): Some evidence suggests that citicoline supplementation may have beneficial effects on attention and behavior in children and adolescents with ADHD. Citicoline's role in supporting neurotransmitter function and brain metabolism may contribute to its potential therapeutic effects in ADHD.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 5.1 | 0.9 | 4.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.9 | 2.5 | 0.16 |
| Allergies | 6.9 | 3.7 | 0.86 |
| Allergy to milk products | 1.8 | 1.6 | 0.13 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.2 | 6.9 | 0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 0.7 | 5.14 |
| Ankylosing spondylitis | 4.9 | 1 | 3.9 |
| Anorexia Nervosa | 1.3 | 2.9 | -1.23 |
| Antiphospholipid syndrome (APS) | 1.7 | 0.3 | 4.67 |
| Asthma | 5.3 | 3.4 | 0.56 |
| Atherosclerosis | 1.9 | 3 | -0.58 |
| Atrial fibrillation | 3.8 | 3.1 | 0.23 |
| Autism | 9.8 | 11.1 | -0.13 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.9 | 1.9 | -1.11 |
| Carcinoma | 4.7 | 2.3 | 1.04 |
| Celiac Disease | 3.1 | 4 | -0.29 |
| Cerebral Palsy | 1.9 | 1 | 0.9 |
| Chronic Fatigue Syndrome | 4.4 | 7.5 | -0.7 |
| Chronic Kidney Disease | 3.6 | 2.8 | 0.29 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2 | -0.33 |
| Chronic Urticaria (Hives) | 1.5 | 1.8 | -0.2 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1 | 0.5 |
| Cognitive Function | 3.3 | 1.6 | 1.06 |
| Colorectal Cancer | 7.5 | 2.3 | 2.26 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 1.7 | 3 | -0.76 |
| COVID-19 | 10.9 | 12.3 | -0.13 |
| Crohn's Disease | 9.2 | 6.6 | 0.39 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.9 | -1.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 3.5 | 1.1 | 2.18 |
| Denture Wearers Oral Shifts | 1.7 | 1.7 | |
| Depression | 11.4 | 10.8 | 0.06 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 2.1 | -0.17 |
| Endometriosis | 3 | 1.8 | 0.67 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.6 | 2.9 | 0.24 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 3.4 | 2.6 | 0.31 |
| Functional constipation / chronic idiopathic constipation | 6.1 | 3.5 | 0.74 |
| gallstone disease (gsd) | 3.1 | 1.6 | 0.94 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 2.9 | 3 | -0.03 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 1 | 0.2 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 3.5 | 1.7 | 1.06 |
| Heart Failure | 4.2 | 2.1 | 1 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.1 | 0.3 | 2.67 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 2.1 | 2.2 | -0.05 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.9 | 6.6 | -0.35 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.2 | 0.9 | 2.56 |
| IgA nephropathy (IgAN) | 1.6 | 5.1 | -2.19 |
| Inflammatory Bowel Disease | 9.3 | 10.7 | -0.15 |
| Insomnia | 2 | 3.2 | -0.6 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 1.1 | 0.9 | 0.22 |
| Irritable Bowel Syndrome | 7.8 | 6.1 | 0.28 |
| ischemic stroke | 3 | 1.7 | 0.76 |
| Liver Cirrhosis | 7.9 | 5.2 | 0.52 |
| Long COVID | 7.6 | 8.4 | -0.11 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1 | 1.3 | -0.3 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 1.2 | 2.4 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 7.8 | 9.3 | -0.19 |
| Mood Disorders | 11.4 | 8.7 | 0.31 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 7 | 6.3 | 0.11 |
| Multiple system atrophy (MSA) | 1.8 | 0.4 | 3.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.8 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.4 | 5.6 | -0.04 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.5 | 8.8 | 0.19 |
| obsessive-compulsive disorder | 5.9 | 3.8 | 0.55 |
| Osteoarthritis | 2.5 | 1.4 | 0.79 |
| Osteoporosis | 2.2 | 1.9 | 0.16 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 8.5 | 7.1 | 0.2 |
| Polycystic ovary syndrome | 6.5 | 2.8 | 1.32 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.5 | 2.4 | 0.04 |
| Psoriasis | 3.6 | 4 | -0.11 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.2 | 4.7 | 0.74 |
| Rosacea | 0.3 | 1 | -2.33 |
| Schizophrenia | 7.1 | 3.3 | 1.15 |
| scoliosis | 0.4 | 0.9 | -1.25 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 1.9 | 1.5 | 0.27 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.6 | 2 |
| Stress / posttraumatic stress disorder | 3.3 | 3.1 | 0.06 |
| Systemic Lupus Erythematosus | 4.4 | 1.6 | 1.75 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.8 | 4.1 | 0.17 |
| Type 2 Diabetes | 8.8 | 8.9 | -0.01 |
| Ulcerative colitis | 5.9 | 8.6 | -0.46 |
| Unhealthy Ageing | 5.8 | 2.9 | 1 |
| Vitiligo | 2.2 | 2 | 0.1 |
